ARTICLE | Company News
Genentech, ImmunoGen deal
May 15, 2006 7:00 AM UTC
The companies partnered to develop a commercial scale manufacturing process for DNA's trastuzumab-DM1 cancer therapeutic, which is in Phase I testing. The compound combines IMGN's DM1 toxin linked to DNA's trastuzumab antibody, which targets HER2. DNA markets Herceptin trastuzumab for breast cancer. ...